K. Peggs

E. Estey, D. Maloney, D. Porter, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adoptive Cellular Therapy: A Therapeutic Reality?

S. Mackinnon, K. Peggs, 2002, Hematology.

Donor lymphocyte infusion in bone marrow transplantation therapy

S. Mackinnon, K. Peggs, 2002 .

Immunotherapy: opportunities, risks and future perspectives.

H. Heslop, C. Bollard, K. Peggs, 2014, Cytotherapy.

Allogeneic transplantation for Hodgkin lymphoma

K. Peggs, P. Anderlini, A. Sureda, 2008, British journal of haematology.

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report

T. Marafioti, K. Ardeshna, K. Peggs, 2021, EJHaem.

The Extended CD 28 : B 7 Immunoglobulin Superfamily

J. Allison, A. Korman, K. Peggs, 2007 .

Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells

Graham M Lord, Richard G. Jenner, A. Akarca, 2020, Immunity.

Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

R. Blasberg, S. Quezada, J. Allison, 2010, The Journal of experimental medicine.

The T cell differentiation landscape is shaped by tumour mutations in lung cancer

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Cancer.

The incidence and cause of coagulopathies in an intensive care population

K. Peggs, T. Littlewood, R. Chakraverty, 1996, British journal of haematology.

Consensus Grading for Cytokine Release Syndrome and Neurologic D 224 X X Toxicity Associated with Immune Effector Cells

S. Grupp, J. Dipersio, K. Peggs, 2019 .

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

S. Grupp, J. Dipersio, M. V. D. van den Brink, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

S. Quezada, J. Allison, K. Peggs, 2006, The Journal of clinical investigation.

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

M. Abbasian, K. Peggs, F. Farzaneh, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

S. Quezada, J. Allison, A. Korman, 2009, The Journal of experimental medicine.

Clinical implications of immune reconstitution following hematopoietic stem cell transplantation.

K. Peggs, C. Mackall, A. Krauss, 2009, Cancer treatment and research.

Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans.

K. Peggs, 2006, Cytotherapy.

First Reported Outbreak of Diarrhea Due to Adenovirus Infection in a Hematology Unit for Adults

J. Tang, R. Tedder, K. Peggs, 2005, Journal of Clinical Microbiology.

A clonal expression biomarker associates with lung cancer mortality

Angela E. Leek, Z. Szallasi, R. Booton, 2019, Nature Medicine.

Current practice in vitamin D assessment and management across the Adult and Paediatric Haematopoietic Stem Cell Transplant Centres in Europe: a survey by the Transplant Complications Working Party of the EBMT

H., J. Snowden, K. Peggs, 2020 .

Current practice in vitamin D management in Allogeneic Haematopoietic Stem Cell Transplantation: a survey by the Transplant Complications Working Party of the EBMT.

J. Snowden, K. Peggs, D. Greenfield, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The importance of age, fludarabine, and total body irradiation in the incidence and severity of chronic renal failure after allogeneic hematopoietic cell transplantation.

J. Delgado, M. Jarmulowicz, S. Mackinnon, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.

S. Mackinnon, K. Peggs, A. Hunter, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.

S. Mackinnon, K. Peggs, P. Ell, 2010, Blood.

lymphoma transplantation regimen for relapsed and refractory non-Hodgkin Outcomes after alemtuzumab-containing reduced-intensity allogeneic

C. Craddock, S. Mackinnon, K. Peggs, 2008 .

Mini‐BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory DLBCL

K. Ardeshna, I. Kayani, K. Peggs, 2012, British journal of haematology.

Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma

K. Ardeshna, I. Kayani, K. Peggs, 2014, British journal of haematology.

Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma

S. Quezada, J. Allison, K. Peggs, 2008, The Journal of experimental medicine.

Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes

J. Garcia-conde, J. Sierra, S. Mackinnon, 2007, British journal of haematology.

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

C. Craddock, S. Mackinnon, K. Peggs, 2005, The Lancet.

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma

N. Russell, K. Peggs, A. Hunter, 2018, British journal of haematology.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

S. Montoto, I. Yakoub-Agha, D. Blaise, 2018, Cancer.

Autologous stem cell transplantation remains beneficial for patients relapsing after R‐CHOP chemotherapy and who respond to salvage chemotherapy

K. Ardeshna, K. Peggs, D. Linch, 2012, British journal of haematology.

Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.

I. Kayani, S. Mackinnon, K. Peggs, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.

S. Mackinnon, K. Peggs, D. Linch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate—gold standards and silver linings

K. Peggs, 2004, Clinical and Experimental Medicine.

Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma.

S. Mackinnon, K. Peggs, K. Yong, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy

K. Peggs, 2004, Expert review of anti-infective therapy.

Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis

H. Einsele, F. Baldanti, G. Fahle, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Allo-HSCT in transplant-naïve patients with Hodgkin lymphoma: a single-arm, multicenter study.

N. Russell, I. Kayani, S. Mackinnon, 2019, Blood advances.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

N. Russell, I. Kayani, S. Mackinnon, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Recent advances in antibody‐based therapies for Hodgkin Lymphoma

K. Peggs, 2015, British journal of haematology.

Regulatory TCells Restrain Interleukin-2- andBlimp- 1-Dependent Acquisition of Cytotoxic Function by CD4 T Cells

Graham M Lord, Richard G. Jenner, A. Akarca, 2020 .

Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma

S. Quezada, K. Peggs, 2010, Expert review of anticancer therapy.

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

S. Montoto, I. Yakoub-Agha, D. Blaise, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment

C. Swanton, T. Powles, A. Feber, 2018, The Journal of experimental medicine.

Immune Reconstitution following Stem Cell Transplantation

K. Peggs, 2004, Leukemia & lymphoma.

Immune reconstitution following haematopoietic stem cell transplantation

S. Mackinnon, K. Peggs, 2004, British journal of haematology.

Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection.

P. Moss, S. Mackinnon, K. Peggs, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

K. Peggs, C. Roddie, 2011, Expert opinion on biological therapy.

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

S. Mackinnon, K. Peggs, D. Linch, 2004, Blood.

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4

S. Quezada, K. Peggs, 2018, Clinical Cancer Research.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

C. Craddock, S. Nagra, L. Jardine, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts

C. Craddock, S. Nagra, L. Jardine, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The Impact of Alemtuzumab Scheduling on Graft Versus Host Disease Following Unrelated Donor Fludarabine and Melphalan Allografts

C. Craddock, S. Nagra, L. Jardine, 2017 .

Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.

K. Peggs, E. Morris, J. Sive, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Brentuximab Vedotin for relapsed Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a report from the EBMT Lymphoma Working Party

S. Montoto, I. Yakoub-Agha, D. Blaise, 2020 .

Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure

K. Ardeshna, K. Peggs, D. Linch, 2014, British journal of haematology.

High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.

S. Mackinnon, K. Peggs, S. Verfuerth, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Etoposide, methylprednisolone, cytarabine and cisplatin successfully cytoreduces resistant myeloma patients and mobilizes them for transplant without adverse effects

K. Ardeshna, K. Peggs, A. Goldstone, 2004, British journal of haematology.

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report

S. Quezada, K. Peggs, J. Larkin, 2015, Cancer Immunology, Immunotherapy.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party

S. Montoto, J. Sierra, D. Blaise, 2018, British journal of haematology.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation

F. Percival, J. Radford, R. Malladi, 2017, Bone Marrow Transplantation.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

K. Peggs, 2018, Blood advances.

Management of cytomegalovirus infection in haemopoietic stem cell transplantation

K. Peggs, V. Emery, A. Clark, 2013, British journal of haematology.

Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia.

C. Craddock, S. Mackinnon, K. Peggs, 2001 .

Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.

K. Ardeshna, S. Mackinnon, K. Peggs, 2009 .

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

S. Montoto, N. Kröger, J. Sierra, 2018, Bone Marrow Transplantation.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma

K. Ardeshna, K. Peggs, D. Linch, 2015, British journal of haematology.

Cytomegalovirus infection and disease after autologous CD34-selected peripheral blood stem cell transplantation for multiple myeloma: no evidence of increased incidence based on polymerase-chain-reaction monitoring

S. Mackinnon, K. Peggs, A. Goldstone, 2000 .

K. Peggs, S. Ings, A. Goldstone, 2000, Blood.

T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions

S. Mackinnon, K. Peggs, S. Verfuerth, 2003, British journal of haematology.

Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.

S. Mackinnon, K. Peggs, G. Hale, 2003, Blood.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

PD-1 blockade: promoting endogenous anti-tumor immunity

S. Quezada, K. Peggs, 2012, Expert review of anticancer therapy.

Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

I. Amit, Eyal David, S. Quezada, 2022, Nature Cancer.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

H. Einsele, A. Zander, G. Gahrton, 2005, Blood.

To the editor: CD34 (cid:1) cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion

S. Mackinnon, K. Peggs, 2003 .

Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial.

E. Tholouli, S. Mackinnon, K. Peggs, 2022, Cytotherapy.

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.

S. Mackinnon, K. Peggs, G. Hale, 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update

K. Peggs, R. Sellar, 2014, Expert opinion on biological therapy.

Improving cellular therapies in Epstein – Barr virus-associated Hodgkin's lymphoma: shifting the equilibrium between effectors and regulators

K. Peggs, 2006, Leukemia & lymphoma.

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

S. Mackinnon, K. Peggs, A. Hunter, 2008, Bone Marrow Transplantation.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

C. Craddock, S. Mackinnon, K. Peggs, 2002, Blood.

Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

R. Benjamin, S. Mackinnon, K. Peggs, 2013, British journal of haematology.

Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study.

P. Hari, K. Peggs, Deepali Kumar, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles

K. Peggs, K. Thomson, M. Marzolini, 2016, British journal of haematology.

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM

K. Peggs, D. Linch, E. Morris, 2016, Bone Marrow Transplantation.

A novel predictive algorithm to personalize autologous T-cell harvest for chimeric antigen receptor T-cell manufacture.

K. Peggs, S. Ings, Carmen Balsa, 2022, Cytotherapy.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes

J. Snowden, K. Peggs, D. Greenfield, 2017, Bone Marrow Transplantation.

Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes

J. Snowden, K. Peggs, D. Greenfield, 2017, Bone Marrow Transplantation.

Allogeneic transplantation in the UK: an aggregation of marginal gains?

K. Peggs, K. Thomson, 2013, British journal of haematology.

Identification of Prognostic Factors Predicting the Outcome of Reduced Intensity Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma. An Analysis from the Lymphoma Working Party of the EBMT

N. Schmitz, C. Craddock, K. Peggs, 2008 .

Natural history of EBV replication and viral load dynamics after alemtuzumab based allogeneic stem cell transplantation.

K. Peggs, R. Hough, E. Sanchez, 2021, Transplantation and cellular therapy.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

A. Pettitt, C. Crawley, J. Snowden, 2010, Blood.

Post-transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion

S. Mackinnon, K. Peggs, K. Thomson, 2003, Bone Marrow Transplantation.

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

Crispin J. Miller, Nicolai J. Birkbak, Angela E. Leek, 2019, Nature Medicine.

Management of multidrug‐resistant viruses in the immunocompromised host

K. Peggs, R. Sellar, 2012, British journal of haematology.

Background to hematopoietic cell transplantation, including post transplant immune recovery

K. Peggs, A. Toubert, T. Fry, 2009, Bone Marrow Transplantation.

Life after allogeneic bone marrow transplant.

K. Peggs, C. Hockings, 2012, British journal of hospital medicine.

Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

K. Peggs, M. Boeckh, W. Murphy, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function.

S. Mackinnon, K. Peggs, R. Hough, 2019, Haematologica.

Cell therapy for cytomegalovirus infection

K. Peggs, L. Neill, 2020, Expert opinion on biological therapy.

Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation

R. Tedder, S. Mackinnon, K. Peggs, 2000, British journal of haematology.

Therapeutic strategies for the prevention and treatment of cytomegalovirus infection

K. Peggs, R. Sellar, 2012, Expert opinion on biological therapy.

reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem

C. Fegan, S. Mackinnon, K. Peggs, 2008 .

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

C. Craddock, C. Fegan, S. Mackinnon, 2002, Blood.

In vitro comparison of currently available and investigational antiviral agents against pathogenic human double‐stranded DNA viruses: A systematic literature review

K. Peggs, J. Hill, S. Voigt, 2019, Antiviral research.

Diagnosis of Neuroinvasive Astrovirus Infection in an Immunocompromised Adult With Encephalitis by Unbiased Next-Generation Sequencing

Vanya Gant, Rahul Phadke, Steve Miller, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

K. Peggs, A. Thrasher, W. Qasim, 2016, Cytotherapy.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

M. Piris, A. Akarca, T. Marafioti, 2017, Nature Medicine.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells

Adrian J. Thrasher, Waseem Qasim, Stuart Adams, 2017, Science Translational Medicine.

Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.

Aymeric Duclert, Laurent Poirot, Martin Pule, 2015, Cancer research.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

T. Marafioti, S. Quezada, K. Peggs, 2014, Blood.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

J. Wolchok, S. Quezada, J. Allison, 2013, The Journal of experimental medicine.

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

S. Quezada, L. Poirot, K. Peggs, 2016, Cancer research.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Angela E. Leek, R. Booton, A. Nicholson, 2018, Cancer cell.

Epitope landscape in breast and colorectal cancer.

K. Kinzler, B. Vogelstein, V. Velculescu, 2008, Cancer research.

Neoantigen-directed immune escape in lung cancer evolution

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2019, Nature.

The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.

S. Quezada, B. Chain, K. Peggs, 2018, Cold Spring Harbor perspectives in medicine.

The function and dysfunction of memory CD8+ T cells in tumor immunity

C. Swanton, S. Quezada, K. Peggs, 2018, Immunological reviews.

Donor whole blood DNA methylation is not a strong predictor of acute graft versus host disease in unrelated donor allogeneic haematopoietic cell transplantation

P. Dhami, V. Rakyan, A. Feber, 2022, medRxiv.

Using DNA sequencing data to quantify T cell fraction and therapy response

Angela E. Leek, Z. Szallasi, R. Booton, 2021, Nature.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

S. Quezada, K. Peggs, A. Furness, 2016, Immunotherapy.

Tumour heterogeneity and immune-modulation

C. Swanton, M. Jamal-Hanjani, S. Quezada, 2013, Current opinion in pharmacology.

Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities.

S. Quezada, K. Peggs, 2011, Immunotherapy.

Geospatial immune variability illuminates differential evolution of lung adenocarcinoma

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Medicine.

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer

S. Quezada, K. Peggs, 2013, British Journal of Cancer.

Evolving adoptive cellular therapies in urological malignancies.

C. Swanton, S. Quezada, K. Peggs, 2017, The Lancet. Oncology.

dendritic cells repertoire diversity following in vitro restimulation by antigen-pulsed specific CD8+ T-cell - Characterization of human cytomegalovirus peptide

P. Moss, S. Mackinnon, K. Peggs, 2013 .

Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Mark Cobbold, Iftekhar Khan, Caroline Dive, 2014, PLoS biology.

Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

Peter Schmid, Marcin Skrzypski, Allan Hackshaw, 2019, Nature Medicine.

Biomarkers of Response to Immune Modulatory Therapies in Cancer

S. Quezada, K. Peggs, A. Furness, 2015 .

A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2022, Nature Cancer.

Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry.

G. Salles, P. Chevallier, D. Blaise, 2021, Cytotherapy.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

S. Quezada, K. Peggs, L. Menger, 2015, Molecular oncology.

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

K. Peggs, P. Veys, S. Samarasinghe, 2015 .

Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.

P. Chiodini, K. Peggs, Z. Jaunmuktane, 2019, The Lancet. Infectious diseases.

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle

S. Quezada, K. Peggs, M. Marzolini, 2015, EMJ Oncology.

Emerging options for the treatment of melanoma – focus on ipilimumab

K. Peggs, C. Roddie, 2014, ImmunoTargets and therapy.

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

S. Quezada, J. Allison, A. Korman, 2006, Current opinion in immunology.

Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.

J. Allison, N. Segal, K. Peggs, 2007, Cancer cell.

Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

S. Quezada, J. Allison, K. Peggs, 2008, Immunological reviews.

Immunotherapy for transplantation-associated viral infections

K. Peggs, C. Roddie, 2017, The Journal of clinical investigation.

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.

S. Grace, S. Mackinnon, K. Peggs, 2018, Blood.

CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion.

S. Mackinnon, K. Peggs, S. Ings, 2004, Blood.

Assessing diversity: immune reconstitution and T‐cell receptor BV spectratype analysis following stem cell transplantation

S. Mackinnon, K. Peggs, S. Verfuerth, 2003, British journal of haematology.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols

C. Craddock, C. Crawley, N. Russell, 2016, British journal of haematology.

HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.

A. Mead, S. Mackinnon, K. Peggs, 2010, Blood.

Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma.

R. Tedder, S. Mackinnon, K. Peggs, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation

K. Peggs, C. Roddie, Vedika Mehra, 2020, Frontiers in Immunology.

Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.

K. Peggs, R. Sellar, 2012, Future oncology.

Predominant or complete recipient T‐cell chimerism following alemtuzumab‐based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure

S. Mackinnon, K. Peggs, E. Morris, 2012, British journal of haematology.

Role of allogeneic stem cell transplantation in multiple myeloma

K. Peggs, K. Thomson, 2005, Expert review of anticancer therapy.

nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following

G. Morgan, S. Mackinnon, K. Peggs, 2013 .

A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte depleted allogeneic haematopoietic stem cell transplant.

J. Snowden, K. Peggs, K. Hoschler, 2019, Vaccine.

Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen.

S. Mackinnon, K. Peggs, D. Linch, 2002, Blood.

Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience

K. Ardeshna, S. Morris, K. Peggs, 2012, Leukemia & lymphoma.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

Nicolai J. Birkbak, Angela E. Leek, R. Booton, 2017, Immunity.

Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia

P. Vyas, C. Craddock, S. Nagra, 2010, Haematologica.

Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.

C. Craddock, N. Russell, S. Mackinnon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.

S. Quezada, S. Mackinnon, K. Peggs, 2015, Blood.

Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists

S. Quezada, J. Allison, K. Peggs, 2009, Clinical and experimental immunology.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

C. Craddock, S. Mackinnon, K. Peggs, 2004, Blood.

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication

S. Quezada, J. Allison, K. Peggs, 2011, Immunological reviews.

Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily

J. Allison, K. Peggs, 2005, British journal of haematology.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas

Charles Swanton, Nicholas McGranahan, M. Gerlinger, 2013, The Journal of pathology.

Guidelines for the management of diffuse large B‐cell lymphoma

K. Peggs, S. Barrington, T. Illidge, 2016, British journal of haematology.

Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Genetics.

Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24

B. Chain, K. Peggs, A. Pizzey, 2005, Clinical Cancer Research.

The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.

J. Delgado, J. Sierra, R. Benjamin, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of allogeneic transplantation in non‐Hodgkin's lymphoma

S. Mackinnon, K. Peggs, D. Linch, 2005, British journal of haematology.

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.

S. Quezada, K. Peggs, F. Vargas, 2014, Trends in immunology.

Cellular therapy: donor lymphocyte infusion

S. Mackinnon, K. Peggs, K. Peggs, 2001, Current opinion in hematology.

Phase I Study of High-Stringency CD8 Depletion of Donor Leukocyte Infusions After Allogeneic Hematopoietic Stem Cell Transplantation

S. Mackinnon, K. Peggs, M. Lowdell, 2009, Transplantation.

The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma

N. Russell, J. Cavenagh, K. Peggs, 2003, British journal of haematology.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

A. Akarca, T. Marafioti, S. Quezada, 2020, Nature Cancer.

Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines

P. Moss, S. Mackinnon, K. Peggs, 2003, The Lancet.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR‐ligand mismatch after dose‐reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma

N. Kröger, S. Iacobelli, A. Zander, 2005, British journal of haematology.

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.

Stephen Mackinnon, S. Mackinnon, K. Peggs, 2003, The New England journal of medicine.

Immunity Report Fc-Optimized Anti-CD 25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

M. Gore, C. Swanton, B. Challacombe, 2017 .

Cytotoxic T Cells for Infections: From Donor Specific to “Off the Shelf”

K. Peggs, M. Marzolini, 2018, Advances and Controversies in Hematopoietic Transplantation and Cell Therapy.

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

P. Moss, S. Quezada, K. Peggs, 2015, Blood.

Cytomegalovirus-specific T-cell therapies: current status and future prospects.

K. Peggs, E. Nicholson, 2015, Immunotherapy.

Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

K. Peggs, M. Boeckh, W. Murphy, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation.

K. Peggs, R. Sellar, 2012, Cytotherapy.

Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.

S. Mackinnon, K. Peggs, M. Lowdell, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adoptive T cell immunotherapy for cytomegalovirus

K. Peggs, 2009, Expert opinion on biological therapy.

Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.

S. Mackinnon, K. Peggs, S. Verfuerth, 2008, Blood cells, molecules & diseases.

Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

S. Mackinnon, K. Peggs, S. Verfuerth, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Effect of In Vivo T-Cell Depletion with Alemtuzumab on Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Delgado, J. Miguel, J. Sierra, 2007 .

Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation.

S. Mackinnon, K. Peggs, 2004, The international journal of biochemistry & cell biology.

Successful translation and future prospects of TALEN editing for leukemia patients

K. Peggs, Mariana Werner Sunderland, 2018, Expert opinion on biological therapy.

Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies

K. Peggs, 2011, Expert review of anticancer therapy.

Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.

S. Mackinnon, K. Peggs, 2004, Human immunology.

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors

P. Dhami, A. Akarca, T. Marafioti, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

CMV-specific cellular therapy for acute myeloid leukemia?

S. Mackinnon, K. Peggs, K. Thomson, 2012, Blood.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation

S. Beck, M. Widschwendter, V. Rakyan, 2015, Genome Medicine.

Reduced intensity transplantation: where are we now?

S. Mackinnon, K. Peggs, E. Morris, 2004, The Hematology Journal.

Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure

K. Ardeshna, K. Peggs, D. Linch, 2011 .

Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy.

K. Peggs, A. Laurence, C. Roddie, 2021, The Lancet Haematology.

Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder

K. Peggs, N. Cross, K. Waghorn, 2009, Bone Marrow Transplantation.

Attack of the T-cell clones.

K. Peggs, 2013, Blood.

TARGETING THE T‐CELL RECEPTOR Β‐CONSTANT DOMAIN FOR IMMUNOTHERAPY OF T‐CELL MALIGNANCIES

A. Akarca, K. Peggs, D. Linch, 2017 .

Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL).

C. Craddock, S. Mackinnon, K. Peggs, 2002 .

Comparison between Anti-Thymocyte Globulin and Alemtuzumab and the Possible Impact of KIR-Ligand Mismatch in Melphalan/Fludarabine Dose-Reduced Conditioning Followed by HLA-Matched and Mismatched Unrelated Stem Cell Transplantation in Patients with Multiple Myeloma.

S. Iacobelli, A. Nagler, K. Peggs, 2004 .

Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning

M. Singer, S. Mackinnon, K. Peggs, 2013, British journal of haematology.

Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer

Angela E. Leek, Z. Szallasi, R. Booton, 2020, Nature Medicine.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

Ashwini Naik, Allan Hackshaw, Zoltan Szallasi, 2017, Nature.

An antitumor boost to TH9 cells

S. Quezada, K. Peggs, 2014, Nature Immunology.

Lung adenocarcinoma promotion by air pollutants

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2023, Nature.

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Angela E. Leek, Robin L. Jones, Z. Szallasi, 2023, Nature.

Genomic–transcriptomic evolution in lung cancer and metastasis

Angela E. Leek, Z. Szallasi, A. Nicholson, 2023, Nature.

Evolutionary characterisation of lung adenocarcinoma morphology in TRACERx

David R. Jones, Angela E. Leek, Z. Szallasi, 2023, Nature Medicine.

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Angela E. Leek, Z. Szallasi, A. Nicholson, 2023, Nature.

The evolution of lung cancer and impact of subclonal selection in TRACERx

Nicolai J. Birkbak, Angela E. Leek, D. M. Miedema, 2023, Nature.

The evolution of non-small cell lung cancer metastases in TRACERx

Nicolai J. Birkbak, Angela E. Leek, Z. Szallasi, 2023, Nature.

Body composition and lung cancer-associated cachexia in TRACERx

Angela E. Leek, N. Perrimon, Z. Szallasi, 2023, Nature Medicine.

A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft

K. Peggs, D. Linch, A. Goldstone, 2007, Leukemia & lymphoma.

Long-term follow-up of an alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant (RIT) regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL)

C. Craddock, S. Mackinnon, K. Peggs, 2004 .

ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

M. Abbasian, K. Peggs, F. Farzaneh, 2020 .

Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

C. Burton, J. Radford, K. Ardeshna, 2017, British journal of haematology.

Long-term outcomes of myeloablation and autologous transplantation of relapsed acute myeloid leukemia in second remission: a British Society of Blood and Marrow Transplantation registry study.

C. Craddock, J. Snowden, K. Peggs, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma.

E. Tholouli, K. Ardeshna, K. Peggs, 2023, Blood.

AVELUMAB MONOTHERAPY FOLLOWED BY A PET ADAPTED CHEMOTHERAPY APPROACH IN THE FIRST LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA: INITIAL RESULTS FROM THE AVENUE WINDOW STUDY

C. Burton, K. Peggs, S. Barrington, 2023, Hematological Oncology.

Letermovir prophylaxis in T-cell–depleted transplants: breakthrough and rebound infections in the postmarketing setting

E. Tholouli, J. Byrne, J. Snowden, 2021, Blood Advances.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

G. Morgan, S. Mackinnon, K. Peggs, 2000, Blood.

Development and evaluation of an internally controlled semiautomated PCR assay for quantification of cell‐free cytomegalovirus

R. Tedder, S. Mackinnon, K. Peggs, 2002, Journal of medical virology.

Astrovirus Infection in an Immunocompromised Adult With Encephalitis by Unbiased Next-Generation Sequencing

V. Gant, K. Peggs, J. Garson, 2015 .

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival

K. Peggs, H. Dolstra, A. Hotblack, 2023, Journal for ImmunoTherapy of Cancer.

AUTO1, a Novel Fast Off CD19CAR Delivers Durable Remissions and Prolonged CAR T Cell Persistence with Low CRS or Neurotoxicity in Adult ALL

K. Peggs, H. Lowe, K. Champion, 2019, Blood.

Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.

K. Peggs, A. Thrasher, W. Qasim, 2016, Cytotherapy.

Exploiting graft-versus-tumour responses using donor leukocyte infusions.

S. Mackinnon, K. Peggs, K. Peggs, 2001, Best practice & research. Clinical haematology.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

S. Quezada, K. Peggs, K. Bergerhoff, 2015, Molecular oncology.

Tumor-Associated Antigen Presentation by γδ T-Cells in Cancer Immunotherapy

K. Peggs, K. Gustafsson, M. Yan, 2014 .

Attack of the T-cell clones.

K. Peggs, 2013, Blood.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma

K. Ardeshna, K. Peggs, D. Linch, 2015, British journal of haematology.

University of Birmingham Tracking genomic cancer evolution for precision medicine : the lung TRACERx study

R. Booton, H. Davies, S. Horswell, 2014 .

Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia

R. Benjamin, S. Mackinnon, K. Peggs, 2013, British journal of haematology.

Use of 18F‐FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions

S. Mackinnon, K. Peggs, P. Ell, 2005, British journal of haematology.

In vitro comparison of currently available and investigational antiviral agents against pathogenic human double‐stranded DNA viruses: A systematic literature review

K. Peggs, S. Voigt, R. Chemaly, 2019, Antiviral research.

Fcγ receptors and immunomodulatory antibodies in cancer

S. Quezada, K. Peggs, F. Gálvez-Cancino, 2023, Nature reviews. Cancer.

Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

K. Peggs, M. Boeckh, W. Murphy, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical trials with CMV-specific T cells.

S. Mackinnon, K. Peggs, K. Peggs, 2002, Cytotherapy.

Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions.

S. Mackinnon, K. Peggs, S. Verfuerth, 2001, Blood.

Targeting interference of CTLA-4 co-inhibition to tumour specific T cells to enhance activity and reduce toxicity

S. Quezada, K. Peggs, C. Roddie, 2016 .

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution

Nicolai J. Birkbak, Z. Szallasi, M. Hayward, 2017, Nature.

Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

Nicolai J. Birkbak, Angela E. Leek, P. Van Loo, 2024, Nature communications.

Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant

P. Hari, K. Peggs, Deepali Kumar, 2023, Open forum infectious diseases.